Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
Open Access
- 26 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 1 (7), e26
- https://doi.org/10.1038/tp.2011.22
Abstract
The purpose of this study was to determine whether the baseline metabolic profile (that is, metabotype) of a patient with major depressive disorder (MDD) would define how an individual will respond to treatment. Outpatients with MDD were randomly assigned to sertraline (up to 150 mg per day) (N=43) or placebo (N=46) in a double-blind 4-week trial. Baseline serum samples were profiled using the liquid chromatography electrochemical array; the output was digitized to create a ‘digital map’ of the entire measurable response for a particular sample. Response was defined as ⩾50% reduction baseline to week 4 in the 17-item Hamilton Rating Scale for Depression total score. Models were built using the one-out method for cross-validation. Multivariate analyses showed that metabolic profiles partially separated responders and non-responders to sertraline or to placebo. For the sertraline models, the overall correct classification rate was 81% whereas it was 72% for the placebo models. Several pathways were implicated in separation of responders and non-responders on sertraline and on placebo including phenylalanine, tryptophan, purine and tocopherol. Dihydroxyphenylacetic acid, tocopherols and serotonin were common metabolites in separating responders and non-responders to both drug and placebo. Pretreatment metabotypes may predict which depressed patients will respond to acute treatment (4 weeks) with sertraline or placebo. Some pathways were informative for both treatments whereas other pathways were unique in predicting response to either sertraline or placebo. Metabolomics may inform the biochemical basis for the early efficacy of sertraline.Keywords
This publication has 46 references indexed in Scilit:
- Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics-Informed PharmacogenomicsClinical Pharmacology & Therapeutics, 2010
- Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with SchizophreniaPLOS ONE, 2010
- Metabolomic Differences in Heart Failure Patients With and Without Major DepressionJournal of Geriatric Psychiatry and Neurology, 2010
- Opioid use affects antioxidant activity and purine metabolism: preliminary resultsHuman Psychopharmacology: Clinical and Experimental, 2009
- Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophreniaMolecular Psychiatry, 2009
- Metabolomics: A Global Biochemical Approach to Drug Response and DiseaseAnnual Review of Pharmacology and Toxicology, 2008
- Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer’s disease: a tale of shotgun lipidomicsJournal of Neurochemistry, 2007
- Alterations in Myocardial Cardiolipin Content and Composition Occur at the Very Earliest Stages of Diabetes: A Shotgun Lipidomics StudyBiochemistry, 2007
- Metabolomic analysis and signatures in motor neuron diseaseMetabolomics, 2005
- Developmental changes in brain kynurenic acid concentrationsDevelopmental Brain Research, 1992